| |
Mean particle size*
(nm)
|
Particles/mL*
|
CD9 + EVs**
S/N ratio MFI
|
|---|
|
Tear fluid
|
|
Pool of patients with pSS (n = 9)
|
255 ± 40
|
5.0 E+08
|
1.04
|
|
Pool of patients with non-SS (n = 14)
|
204 ± 8
|
1.2 E+09
|
1.22
|
|
Pool of controls (n = 10)
|
215 ± 9
|
7.1 E+08
|
1.20
|
|
Saliva
|
|
Patients with pSS (n = 9)
|
233 ± 17
|
1.9 E+10 ± 0.7E+9
|
4.32 ± 1.19
|
|
Patients with non-SS (n = 14)
|
231 ± 13
|
1.0 E+10 ± 1.6E+9
|
3.98 ± 0.57
|
|
Controls (n = 10)
|
264 ± 6
|
7.9 E+9 ± 1.6E+9
|
3.22 ± 0.98
|
- *Nanoparticle tracking analysis was conducted on EV joint fractions from pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls) and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls), to determine mean particle size of microvesicles and exosomes (nm ± SEM), in addition to concentrations of EVs (particles/ml ± SEM)
- **Detection of CD9+ EVs from joint fractions of pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls), and whole saliva (n = 9 pSS, n = 14 non-SS and n = 10 controls) was performed by immunoaffinity capture using anti-CD9 coated magnetic beads followed by flow cytometry analysis. The results were reported as signal to noise (S/N) ratios of median fluorescence intensity (MFI)
